Biomarkers Predictive of Therapeutic Benefit 6

• 7710 · PDF Extracellular vesicle immunopeptidomics recovers immunogenic neoantigen peptides from cancer patient plasma Todd Hembrough, Alan Mark Ezrin, Zackary Opheim, Cheryl Bandoski, Sarah Bennett, Kate Fagan-Solis, Benjamin G. Vincent, William Hoos
• 7712 · PDF Wnt-driven chromosomal instability as a biomarker for PORCN inhibition Diego García-López, Azedine Zoufir, Hector De Galard Terraube, Laura Madrid, Amy Cullen, Ania Piskorz, Nicola Wallis, Ruth Plummer, Steven Jackson, Jackie Walling, James D. Brenton, Florian M. Markowetz, Jason Yip, Jose Teles, Geoff Macintyre
• 7713 Biomarker-guided treatment approach For advanced bladder cancer Dhasarathan Ganesan, Karina Aguilar, Tianyu yang, Bal L. Lokeshwar, Vinata B. Lokeshwar
• 7714 · PDF Extracellular vesicle glycosylation profilepredictsand affectstherapeutic outcomes ofCLDN18.2-targeted CAR-T cell therapyagainst gastrointestinal cancers Wenran Li, Min Tao, Changsong Qi, Lin Shen, Cheng Zhang
• 7715 · PDF Elevated baseline DKK1 plasma is a biomarker for sirexatamab treated colorectal cancer patients Zongzhong Tong, Scott Patton, Patty Ormonde-Hanson, Calvin Jia, Cyndi Sirard, Jay Baum, Mike Kagey
• 7716 · PDF Tumor-intrinsic MHC-II activation in pancreatic ductal adenocarcinoma enhances immune response and treatment efficacy Canping Chen, Kyle P. Gribbin, Xi Li, Tugba Ozmen, Furkan Ozmen, Shamilene Sivagnanam, James Kim, Katie E. Blise, Xinxing Yang, Yi Zhang, Dove Keith, Mara H. Sherman, Mushui Dai, Lisa M. Coussens, Charles D. Lopez, Rosalie C. Sears, Gordon B. Mills, Katelyn T. Byrne, Zheng Xia
• 7717 · PDF TRPM4 expression predicts Acetalax sensitivity in prostate cancer Yuka Hoshi, William C. Reinhold, Daiki Taniyama, Yoshitaka Inoue, Augustin Luna, Suresh Kumar, NAI-YUN SUN, Yoo Sun Kim, Yin Juanjuan, Nitin Roper, Adam G. Sowalsky, Naoko Takebe, Yves Pommier
• 7718 · PDF Stearic acid-macrophage crosstalk identifies MIF-CD44 signaling as a therapeutic target in lung cancer initiation Amrita Roy, Greta Forbes, Dikshaya Prabhakara, Tyler Faith, Apurva Mallisetty, Samuel Weinberg, Alicia Hulbert, Frank D. Weinberg
• 7719 · PDF Exploring biomarker predictors of response to nintedanib and bevacizumab combination therapy in advanced cancer patients: Correlative studies from Phase 1b study Ravi Kumar Paluri, Anup Kasi, Francisco Robert, Gagan Deep, Ashish Manne
• 7720 Differences in FGFR2 fusion detection between DNA and RNA NGS in a large Chinese lung cancer cohort Wenxue Chen, Xinlin Yu, Lipeng Bai, Can Wen, Wennan Zhang, Wanwan Zou, Zhiliang Liu, Ruijia Sun, Mengli Huang
• 7721 · PDF Correlation between PD-L1, desmocollin 3, and stromal lymphocytes in recurrent head and neck squamous cell carcinomas Vedanti Newaskar, Shivani Sharma, Bakulesh M. Khamar
• 7722 · PDF Biomarkers of nelmastobart efficacy: BTN1A1 expression and tumor microenvironment dynamics in colorectal cancer Bong-Ki Hong, Soohyeon Lee, Andrew H. Park, Young-Seung Kim, Chunai Wu, Seung-Hoon Lee, Jong-Su Park, Stephen S. Yoo
• 7723 · PDF Implementation of a novel immune monitoring strategy for multicenter clinical trials to enable equity in cancer prognosis for individuals from remote settings of Australia Natalie J. Smith, Michael Cohen, Lauren J. Tracey, Julie Alipaz, Christina Loh, David A. King, Neha Pulyani, Rebecca Auzins, Elin S. Gray, Sandra Taylor, Rajat Rai, Steven Kao, Barbara Fazekas de St Groth, Helen McGuire
• 7724 · PDF A circulating GPNMB-based multimodal model integrates tumor-immune crosstalk to predict immunotherapy response in esophageal cancer Liang Zhu, Xiaoyuan Wang, Guoyu Cheng, Yancheng Lai, Lan Lan, Zhenghao Dong, Zhixuan You, Xinjie Chen, Ziyi He, Xinyi Xiao, Lingxuan Zhu, Rucheng Liu, Shaosen Zhang, Dongxin Lin, Chen Wu, Jiang Chang
• 7725 · PDF Integrative molecular profiling identifies predictors of response to sacituzumab govitecan in advanced prostate cancer Jacque Lyman, Todd Knutson, Allison Haaning, Braedan M. McCluskey, Yingming Li, Jamie M. Sperger, Rendong Yang, Christos Kyriakopolous, Susan F. Slovin, Scott T. Tagawa, Joshua M. Lang, Scott M. Dehm
• 7726 · PDF Expression profile of therapeutic target CDH17 in gastric cancer Fei Chu, Jiaxing Zhao, Dan Huang, Hao Luo, Aaron Hong, Ye Tian, Chang Liu, David Chu, Jim Lu
• 7727 · PDF Integrated FHIT and IDH2 biomarkers predict synthetic lethal response to DCPS inhibition in acute myeloid leukemia Madhurendra Singh, Francesca Grassi, Lisa Bast, Vladimir Talibov, Camilla Silvander, Simon Moussaud, Matthieu Desroses, Angelo De-Milito, Julian Walfridsson, Andreas Höglund, Martin Andersson
• 7728 · PDF Glycogen branching enzyme 1 as a metabolic determinant and prognostic driver of the CMS4 subtype in colorectal cancer Fang-Chi Hsu, Leila Su, Frank Luh, Yi-Fan Chen, Xin Wang, Yun Yen
• 7729 · PDF Phosphorylated FRS2 (pFRS2) as a biomarker for FGFR mutation or fusion activity assessment in formalin-fixed paraffin-embedded tumor sections Peter Feiszt, Kristopher A. Lofgren, Paraic A. Kenny
• 7730 A novel ultra-sensitive qPCR-based liquid biopsy assay: ESR1 mutation detection in peripheral plasma derived cfDNA Fei Ma, Haili Qian, Wenna Wang, Yongpan Yan, Bowen Ji, Yuwei Pei
• 7731 · PDF Tumor immune microenvironment features associated with response to neoadjuvant durvalumab plus gemcitabine, cisplatin, and nab-paclitaxel (DURGAP) in resectable biliary tract cancer Huiying Yan, Wenxin Li, Linze Xu, Rentao Li, Linlin Fu, Qi Qi, Xihao Zhang, Jihui Hao, Huikai Li, Yang Liu
• 7732 · PDF A stromal-immune spatial transcriptomic signature associated with MUC4 identifies potential biomarkers of trastuzumab resistance in HER2-positive breast cancer Maria F. Mercogliano, Nadine Schrode, Kristin Beaumont, Roxana Schillaci
• 7733 · PDF Reliable antibodies for cancer research: TROP2 as a case study of Abcam's enhanced validation framework Caroline S. Hirst, JK Tanjore Ramanathan, Nadine Nelson, Antonella Galli, Will Howat, Silvia Sbacchi
• 7734 · PDF The gap score: A functional biomarker of drug sensitivity Sharon B. Cantor, Jenna Whalen, Tokio Sano
• 7735 · PDF HER2 expression and tumor-infiltrating lymphocytes predict response to tucatinib plus trastuzumab in HER2 -positive metastatic colorectal cancer (MOUNTAINEER): Exploratory analysis of a multicenter, Phase II trial Mitsuho Imai, John H. Strickler, Woochan Hwang, Kara Bonneau, Andrew B. Nixon, Jongchan Park, Chang Ho Ahn, Tanios Bekaii-Saab, Takayuki Yoshino
• 7736 · PDF Rare EGFR cis compound L833V/H835L mutation in non-small cell lung cancer is oncogenic and a therapeutic target of EGFR tyrosine kinase inhibitors Yo Han Jeon, Ahjin Lim, Myung Kyung Choi, Hee Seong Choi, Yurimi Lee, Hyunju Song, Hyun-Soo Cho, Jeonghee Cho, Yoon-La Choi
• 7737 · PDF Baseline CD16 + NK cells are associated with clinical outcome of nivolumab plus ipilimumab immunotherapy in advanced hepatocellular carcinoma Hongjae Chon, Narim Lee, Hannah Yang, Junho Kang, Won Suk Lee, So Jung Kong, Beodeul Kang, Jung Sun Kim, Ho Yeong Lim, Jung Kyoon Choi, Chan Kim

在完整检索应用中浏览本分会场 →